The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology (“ESMO”) by several companies. Other updates were also in focus. Among ...

Benetrends Financial, a leading provider of funding solutions for entrepreneurs and franchisees, announced today that recent interest rate cuts tied to the Federal Reserve's half-point reduction of ...

Dermavant Sciences Ltd. to Organon & Co. for $1.2 billion. The massive amount comprises an up-front $175 million payment, along with a potential $75 million regulatory milestone and up to $950 million ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Data presented at ESMO 2024 show that givastomig demonstrated continued monotherapy ... and we look forward to sharing the results from this study in the second half of 2025.” Poster Title: Updated ...

The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET ...

Exelixis releases positive phase 3 data on Cabometyx for pancreatic and extra-pancreatic neuroendocrine tumors, seeking ...

Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected ...